WILMINGTON, DE, and MONTREAL, QC, Jan. 18 /PRNewswire-FirstCall/ - Millenia Hope Inc., , stated that its most advanced drug discovery program is HIV-1 RNaseH, for which a patent application has been submitted. HIV-1 RNaseH preliminary results were presented at the 12th conference on Retroviruses and Opportunistic Infections, in Boston in February 2005, by Prof. Michael A. Parniak, of the University of Pittsburgh's School of Medicine, to great interest.
Inquiries were made by pharmaceutical companies, regarding the strong correlation between the results of the bio-chemical and cell-based assays obtained by Millenia Hope. These results are unique for this particular target, HIV-1 RNaseH, and validate it as a highly valued program. Millenia made a strategic decision to further develop this program, before considering partnering with a pharmaceutical company.
Based on the strength of the scientific data obtained so far, we decided to collaborate with Prof. Parniak, a long time collaborator of Millenia Hope, and to submit, under his leadership, a grant application to the National Institute of Health (NIH). To strengthen the application we invited Prof. Eddie Arnold and Prof. Ron Levy, both from Rutgers University, to participate in this application.
We are awaiting, shortly, the decision of the NIH regarding this application.
ABOUT MILLENIA HOPE:
Millenia Hope develops innovative treatments and products that enhance the quality of life, has put in place programs to fight major infectious diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
SAFE HARBOR STATEMENTS:
Certain statements made in the release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Millenia Hope/Millenia Hope Biopharma that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements and Millenia Hope could encounter unanticipated obstacles and delays in developing products, services and markets.
MILLENIA HOPE BIOPHARMA